This product consists of a polyclonal population of HT29 human colorectal adenocarcinoma cells that have undergone CRISPR/Cas9-mediated gene disruption of ACER1, resulting in a loss-of-function model for alkaline ceramidase 1. The polyclonal nature of the knockout pool ensures the capture of diverse genetic alterations across the cell population, providing a robust system for studying ACER1-dependent processes without clonal biases. This knockout model is designed for researchers investigating sphingolipid metabolism and its implications in cancer biology.
The HT29 parental cell line was originally isolated from a primary colorectal adenocarcinoma of a 44-year-old female patient and is widely utilized as an intestinal epithelial model. HT29 cells retain characteristic features of colorectal carcinoma, including aberrant signaling pathways and the capacity for differentiation under appropriate culture conditions. Their use in sphingolipid research is well established, owing to their expression of key ceramide-metabolizing enzymes and responsiveness to lipid-mediated signaling cues, making them an ideal host for ACER1 loss-of-function studies.
The ACER1 gene product catalyzes the hydrolysis of ceramides to sphingosine and fatty acids, a pivotal reaction controlling the equilibrium between pro-apoptotic ceramide and pro-survival sphingosine-1-phosphate (S1P). Its activity is modulated by TNF-??, oxidative stress, retinoic acid, IL-1??, and DNA methylation, and it directly impacts levels of downstream mediators including sphingosine, S1P, p53, BAX, Bcl-2, and caspase-3. ACER1 physically and functionally interacts with sphingosine kinase 1 (SPHK1), ceramide synthases, S1P receptors, and PP2A. Knockout of ACER1 in HT29 cells elevates intracellular ceramide, shifting the BAX/Bcl-2 ratio to favor mitochondrial apoptosis and activating caspase-3, while concurrently diminishing S1P-mediated survival signaling through AKT and ERK pathways.
In HT29 colorectal adenocarcinoma cells, loss of ACER1 accentuates ceramide-driven apoptosis and attenuates S1P-dependent proliferation and survival, potentially enhancing sensitivity to chemotherapeutic agents. This knockout model enables dissection of sphingolipid rheostat dynamics in a malignant intestinal epithelial system and is instrumental for investigating metabolic vulnerabilities, drug resistance mechanisms, and tumor microenvironment interactions in colorectal cancer.
Typical experimental applications include sphingolipidomics by LC-MS to quantify ceramide and sphingoid bases, Western blotting and immunofluorescence for apoptosis markers and ACER1 interactors, Annexin V/PI and caspase activity assays for apoptosis assessment, MTT and colony formation assays for proliferation, phospho-ERK/AKT flow cytometry for signaling pathway analysis, and xenograft tumor models for in vivo evaluation. These applications support research in colorectal cancer, sphingolipid metabolism, drug sensitivity screening, and tumor?Cmicroenvironment crosstalk. Researchers may contact Ascent Research for further technical guidance.
